A team of scientists from the US and the UK have found a new type of prion disease in mice that damages brain arteries and may help us better understand and treat types of Alzheimer’s disease that cause similar damage. You can read a scientific paper about the discovery in the 5 March online issue of the journal PLoS Pathogens…
More: continued here
Pfizer Inc. (NYSE: PFE) and Medivation, Inc. (NASDAQ: MDVN) announced results from two Phase 3 trials of the investigational drug dimebon (latrepirdine*) in patients with Alzheimer’s disease (AD). In the CONNECTION trial, dimebon did not meet its co-primary or secondary efficacy endpoints compared to placebo. Co-primary endpoints were measures of cognition and global function…
More: continued here
In an announcement today, Mount Sinai School of Medicine (MSSM) and Medisyn Technologies, Inc…
More: continued here
Carnegie Mellon University researchers in the Quality of Life Technology Center (QoLTC) will embed wireless sensors in the residences of about 50 older adults who live alone to see if they can detect subtle changes in everyday activities that indicate the onset of dementia or physical infirmities…
More: continued here
A study from EPFL’s (Ecole Polytechnique Federale de Lausanne) Laboratory of Neuroenergetics and Cellular Dynamics in Lausanne Switzerland, published today in the Journal of Neuroscience, may lead to new forms of treatment following a better understanding of how Amyloid-Beta found in cerebral plaques, typically present in the brain of Alzheimer’s patients, may lead to neurodegeneration…
More: continued here
“The Alzheimer’s Association is disappointed to learn of the negative results from the Phase III clinical trial of latrepirdine (Dimebon),” said William Thies, Ph.D., Alzheimer’s Association Chief Medical and Scientific Officer. “People with Alzheimer’s, their families and caregivers desperately need more and better treatment options for this devastating, fatal brain disease…
More: continued here
Researchers have launched a unique project to improve early diagnosis and management of dementia among Deaf people who use British Sign Language (BSL). The research, funded by Alzheimer’s Society, will examine how to identify dementia in Deaf people and explore how they might best cope with their condition…
More: continued here
Model and presenter Nell McAndrew is calling for people to join her in raising money for people with dementia by running for Alzheimer’s Society, Bupa’s nominated charity. Nell’s grandad, Sam, was recently diagnosed with Alzheimer’s disease and she will be running in honour of him…
More: continued here
Alzheimer’s disease affects an estimated 27 million people worldwide. It is the most common form of age-related dementia, possibly the most feared disease of old age. There is no cure, and the available drugs only help to relieve symptoms without slowing progression of the disease…
More: continued here
Greater purpose of life could significantly reduce a person’s chance of developing Alzheimer’s disease according to a study published in the Archives of General Psychiatry. Researchers in Chicago measured purpose of life of 951 older people who did not have dementia over an average of four years…
More: continued here





